Phase II study of niraparib in patients with metastatic castration-resistant prostate cancer (mCRPC) and biallelic DNA-repair gene defects (DRD): Preliminary results of GALAHAD.

被引：39
|
作者：
Smith, Matthew Raymond
Sandhu, Shahneen Kaur
Kelly, William Kevin
Scher, Howard I.
Efstathiou, Eleni
Lara, Primo
Yu, Evan Y.
George, Daniel J.
Chi, Kim N.
Summa, Jason
Kothari, Nishi
Zhao, Xin
Espina, Byron M.
Ricci, Deborah S.
Simon, Jason S.
Tran, Namphuong
Fizazi, Karim
机构：
[1] Massachusetts Gen Hosp, Ctr Canc, Boston, MA USA
[2] Harvard Med Sch, Boston, MA 02115 USA
[3] Peter MacCallum Canc Ctr, Melbourne, Vic, Australia
[4] Thomas Jefferson Univ Hosp, Philadelphia, PA 19107 USA
[5] Mem Sloan Kettering Canc Ctr, 1275 York Ave, New York, NY 10021 USA
[6] Dept Genitourinary Med Oncol, Div Canc Med, Houston, TX USA
[7] Univ Calif Davis, Ctr Comprehens Canc, Sacramento, CA 95817 USA
[8] Univ Washington, Seattle, WA 98195 USA
[9] Duke Canc Inst, Durham, NC USA
[10] Univ British Columbia, BC Canc Vancouver Ctr, Vancouver, BC, Canada
[11] Janssen Res & Dev, Los Angeles, CA USA
[12] Janssen Res & Dev, San Francisco, CA USA
[13] Janssen Res & Dev, Spring House, PA USA
[14] Janssen Res & Dev, Raritan, NJ USA
[15] Univ Paris Sud, Inst Gustave Roussy, Villejuif, France
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2019年 / 37卷 / 07期
关键词：
D O I：
10.1200/JCO.2019.37.7_suppl.202
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
202
引用
收藏
页数：2
相关论文
共 50 条
  • [1] Niraparib in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) and biallelic DNA-repair gene defects (DRD): Correlative measures of tumor response in phase II GALAHAD study
    Smith, Matthew Raymond
    Fizazi, Karim
    Sandhu, Shahneen Kaur
    Kelly, William Kevin
    Efstathiou, Eleni
    Lara, Primo
    Yu, Evan Y.
    George, Daniel J.
    Chi, Kim N.
    Saad, Fred
    Summa, Jason
    Freedman, Jamie M.
    Mason, Gary
    Espina, Byron M.
    Zhu, Eugene
    Ricci, Deborah S.
    Snyder, Linda A.
    Simon, Jason S.
    Cheng, Shinta
    Scher, Howard I.
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (06)
  • [2] Pre-specified interim analysis of GALAHAD: A phase II study of niraparib in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) and biallelic DNA-repair gene defects (DRD)
    Smith, M. R.
    Sandhu, S. K.
    Kelly, W. K.
    Scher, H. I.
    Efstathiou, E.
    Lara, N.
    Yu, E. Y.
    George, D. J.
    Chi, K. N.
    Saad, F.
    Summa, J.
    Freedman, J. M.
    Mason, G. E.
    Zhu, E.
    Ricci, D.
    Simon, J. S.
    Cheng, S.
    Fizazi, K.
    ANNALS OF ONCOLOGY, 2019, 30 : 884 - +
  • [3] Health-related quality of life (HRQoL) at final analysis of the GALAHAD study of niraparib in patients with metastatic castration-resistant prostate cancer (mCRPC) and DNA repair defects (DRD)
    Smith, M. R.
    Sandhu, S. K.
    George, D. J.
    Chi, K. N.
    Saad, F.
    Thiery-Vuillemin, A.
    Stahl, O.
    Olmos, D.
    Danila, D.
    Gafanov, R.
    Castro, E.
    Moon, H.
    Joshua, A. M.
    Mason, G. E.
    Espina, B. M.
    Liu, Y.
    Bevans, K. B.
    Lopez-Gitlitz, A.
    Francis, P.
    Fizazi, K.
    ANNALS OF ONCOLOGY, 2021, 32 : S632 - S633
  • [4] Niraparib in patients with metastatic castration-resistant prostate cancer and DNA repair gene defects (GALAHAD) a multicentre, open-label, phase 2 trial
    Smith, Matthew R.
    Scher, Howard, I
    Sandhu, Shahneen
    Efstathiou, Eleni
    Lara, Primo N.
    Yu, Evan Y.
    George, Daniel J.
    Chi, Kim N.
    Saad, Fred
    Stahl, Olof
    Olmos, David
    Danila, Daniel C.
    Mason, Gary E.
    Espina, Byron M.
    Zhao, Xin
    Urtishak, Karen A.
    Francis, Peter
    Lopez-Gitlitz, Angela
    Fizazi, Karim
    LANCET ONCOLOGY, 2022, 23 (03): : 362 - 373
  • [5] Health-related quality of life in GALAHAD: A multicenter, open-label, phase 2 study of niraparib for patients with metastatic castration-resistant prostate cancer and DNA-repair gene defects
    Smith, Matthew R.
    Sandhu, Shahneen
    George, Daniel J.
    Chi, Kim Nguyen
    Saad, Fred
    Thiery-Vuillemin, Antoine
    Stahl, Olaf
    Olmos, David
    Danila, Daniel C.
    Gafanov, Rustem
    Castro, Elena
    Moon, Helen
    Joshua, Anthony M.
    Mason, Gary E.
    Espina, Byron M.
    Liu, Yan
    Lopez-Gitlitz, Angela
    Francis, Peter
    Bevans, Katherine B.
    Fizazi, Karim
    JOURNAL OF MANAGED CARE & SPECIALTY PHARMACY, 2023, 29 (07): : 758 - 768
  • [6] DNA REPAIR GENE DEFECTS IN AUSTRALIAN MEN WITH METASTATIC CASTRATION-RESISTANT PROSTATE CANCER (MCRPC)
    Banks, Patricia
    Leong, Huei San
    Ryland, Georgie
    Beshay, Victoria
    Tran, Ben
    Toner, Guy
    Murphy, Declan
    Fox, Stephen
    Weickhardt, Andrew
    Pezaro, Carmel
    Thorne, Heather
    Goode, David
    Fellowes, Andrew
    Sandhu, Shahneen
    ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2017, 13 : 58 - 58
  • [7] DNA repair gene defects in Australian men with metastatic castration-resistant prostate cancer (mCRPC)
    Banks, Patricia
    San Leong, Huei
    Ryland, Georgina
    Beshay, Victoria
    Tran, Ben
    Toner, Guy
    Murphy, Declan
    Fox, Stephen
    Weickhardt, Andrew
    Pezaro, Carmel
    Thorne, Heather
    Goode, David
    Fellowes, Andrew
    Sandhu, Shahneen
    BJU INTERNATIONAL, 2017, 120 : 8 - 8
  • [8] Phase II Study with metastatic castration-resistant Prostate Cancer (mCRPC) Patients
    Rexer, H.
    Graefen, M.
    UROLOGE, 2017, 56 (11): : 1468 - 1470
  • [9] Preliminary phase II results of the CYPIDES study of ODM208 in metastatic castration-resistant prostate (mCRPC) cancer patients
    Fizazi, K.
    Bernard-Tessier, A.
    Barthelemy, P.
    Utriainen, T.
    Roubaud, G.
    Flechon, A.
    van der Voet, J. C. M.
    Mescam, G. Gravis
    Ratta, R.
    Jones, R. H.
    Parikh, O. A.
    Tanner, M. M. E.
    Garratt, C.
    Nevalaita, L.
    Pohjanjousi, P.
    Ikonen, T.
    Antonarakis, E. S.
    Cook, N.
    ANNALS OF ONCOLOGY, 2022, 33 (07) : S1165 - S1165
  • [10] Niraparib with Abiraterone Acetate and Prednisone for Metastatic Castration-Resistant Prostate Cancer: Phase II QUEST Study Results
    Chi, Kim N.
    Fleshner, Neil
    Chiuri, Vincenzo Emanuele
    Van Bruwaene, Siska
    Hafron, Jason
    McNeel, Douglas G.
    De Porre, Peter
    Maul, Raymond Scott
    Daksh, Mahesh
    Zhong, Xiaogang
    Mason, Gary E.
    Tutrone, Ronald F.
    ONCOLOGIST, 2023, 28 (05): : E309 - E312
12345